FBB Biomed, headquartered in Coralville, has entered into a Master Services Agreement with Verici Dx plc to provide laboratory services for Research-Use-Only (RUO) tests, as defined by the FDA. These tests aim to support clinicians in exploring advanced insights into neurologic diseases, including Parkinson’s, Alzheimer’s, Multiple Sclerosis, ALS, Depression, Schizophrenia, and long COVID.
As stated in a release from FBB Biomed, the RUO tests are designed to enhance understanding of the root causes of complex neurologic conditions, potentially offering new perspectives for treatment and research.Â
With the global burden of neurologic diseases on the rise, including the increasing prevalence of long COVID cases, this collaboration seeks to equip clinicians with valuable research data to improve patient care, the release states.Â
The agreement facilitates clinicians’ access to these RUO tests focused on addressing chronic neurologic conditions. FBB Biomed, with support from Verici Dx, aims to drive innovation in neurodegenerative disease research. Verici Dx is based in Tennessee.Â
“We are excited to announce this strategic collaboration with Verici Dx, a leader in RNA sequencing,” said Dr. Howard Urnovitz, CEO of FBB Biomed, in the release. “This partnership allows FBB Biomed to offer its innovative RUO tests to early-adopter clinics and clinicians working to advance diagnostics for neurological diseases. This agreement represents a transformative step for our company, moving us from an R&D focus into commercial operations.”
FBB Biomed, located on Crosspark Road in Coralville, specializes in genetics, bioinformatics, and RNA virology to develop treatments for inflammatory diseases. In October, the Iowa Economic Development Authority approved a $250,000 Innovation Acceleration Launch Fund loan from the SSBCI Innovation Fund for FBB Biomed.
